Carol Routledge

Carol Routledge is an Honorary Professor and Entrepreneur in Residence (EIR) at the University of Exeter, with over 30 years of experience in pharmaceutical and biotechnology R&D. Her career spans leadership roles at Syntex, Wyeth, BTG, and GSK, focusing on neuroscience drug development, and she currently serves as Chief Medical & Scientific Officer at Small Pharma, a company developing treatments for mental health disorders. She has also led Alzheimer’s Research UK’s global research strategy and founded the Early Detection of Neurodegenerative diseases (EDoN) initiative.

Education:

• BSc in Zoology (1st Class Honors), University of Nottingham
• PhD in Neuropharmacology and Neuroscience, The Queens Medical Centre, Nottingham

Carol’s research interests integrate neuroscience and clinical development to advance psychedelic-assisted therapies for mental health. She spearheads AI-driven digital tools for early detection of neurodegenerative diseases, advises AI-focused drug discovery companies, and supports academic commercialization through her EIR role. Her work bridges preclinical and clinical translational medicine, targeting psychiatric and neurological conditions like Alzheimer’s.

Leadership and Advisory Roles:

• Managing Director of the Early Detection of Neurodegenerative diseases (EDoN) initiative
• Board member, Alzinova AB (Sweden)
• Steering Committee member and Advisor, EDoN
• Advisory Board member, Ro5 and Cognetivitiy (UK)